{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:21:02Z","timestamp":1790644862141,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N00373X\/1"],"award-info":[{"award-number":["MR\/N00373X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N00373X\/1"],"award-info":[{"award-number":["MR\/N00373X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N00373X\/1"],"award-info":[{"award-number":["MR\/N00373X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Kynurenine 3-monooxygenase (KMO) regulates the levels of neuroactive metabolites in the kynurenine pathway (KP), dysregulation of which is associated with Huntington\u2019s disease (HD) pathogenesis. KMO inhibition leads to increased levels of neuroprotective relative to neurotoxic metabolites, and has been found to ameliorate disease-relevant phenotypes in several HD models. Here, we crossed KMO knockout mice to R6\/2 HD mice to examine the effect of KMO depletion in the brain and periphery. KP genes were dysregulated in peripheral tissues from R6\/2 mice and KMO ablation normalised levels of a subset of these. KP metabolites were also assessed, and KMO depletion led to increased levels of neuroprotective kynurenic acid in brain and periphery, and dramatically reduced neurotoxic 3-hydroxykunurenine levels in striatum and cortex. Notably, the increased levels of pro-inflammatory cytokines TNFa, IL1\u03b2, IL4 and IL6 found in R6\/2 plasma were normalised upon KMO deletion. Despite these improvements in KP dysregulation and peripheral inflammation, KMO ablation had no effect upon several behavioural phenotypes. Therefore, although genetic inhibition of KMO in R6\/2 mice modulates several metabolic and inflammatory parameters, these do not translate to improvements in primary disease indicators\u2014observations which will likely be relevant for other interventions targeted at peripheral inflammation in HD.<\/jats:p>","DOI":"10.1038\/s41598-021-84858-7","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T11:03:14Z","timestamp":1615287794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6\/2 mouse model of Huntington\u2019s disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Marie Katrin","family":"Bondulich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeojin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaviano","family":"Giorgini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian P.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"84858_CR1","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Primers 1, 15005 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"84858_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"ME MacDonald","year":"1993","unstructured":"MacDonald, M. E. et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"84858_CR3","first-page":"16","volume":"59","author":"DC Rubinsztein","year":"1996","unstructured":"Rubinsztein, D. C. et al. Phenotypic characterization of individuals with 30\u201340 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36\u201339 repeats. Am. J. Hum. Genet. 59, 16\u201322 (1996).","journal-title":"Am. J. Hum. Genet."},{"key":"84858_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/hmg\/2.10.1535","volume":"2","author":"H Telenius","year":"1993","unstructured":"Telenius, H. et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum. Mol. Genet. 2, 1535\u20131540 (1993).","journal-title":"Hum. Mol. Genet."},{"key":"84858_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","volume":"57","author":"JPG Vonsattel","year":"1998","unstructured":"Vonsattel, J. P. G. & Difiglia, M. Huntington disease. J. Neuropathol. Exp. Neurol. 57, 369\u2013384 (1998).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"84858_CR6","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","volume":"14","author":"JB Carroll","year":"2015","unstructured":"Carroll, J. B., Bates, G. P., Steffan, J., Saft, C. & Tabrizi, S. J. Treating the whole body in Huntington\u2019s disease. Lancet Neurol. 14, 1135\u20131142 (2015).","journal-title":"Lancet Neurol."},{"key":"84858_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.semcdb.2015.03.002","volume":"40","author":"DC Maddison","year":"2015","unstructured":"Maddison, D. C. & Giorgini, F. The kynurenine pathway and neurodegenerative disease. Semin. Cell Dev. Biol. 40, 134\u2013141 (2015).","journal-title":"Semin. Cell Dev. Biol."},{"key":"84858_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0006-291X(02)02917-0","volume":"300","author":"GI Giles","year":"2003","unstructured":"Giles, G. I., Collins, C. A., Stone, T. W. & Jacob, C. Electrochemical and in vitro evaluation of the redox-properties of kynurenine species. Biochem. Biophys. Res. Commun. 300, 719\u2013724 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"84858_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0014-2999(81)90587-2","volume":"72","author":"TW Stone","year":"1981","unstructured":"Stone, T. W. & Perkins, M. N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 72, 411\u2013412 (1981).","journal-title":"Eur. J. Pharmacol."},{"key":"84858_CR10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/ng1542","volume":"37","author":"F Giorgini","year":"2005","unstructured":"Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C. & Muchowski, P. J. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 37, 526\u2013531 (2005).","journal-title":"Nat. Genet."},{"key":"84858_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"D Zwilling","year":"2011","unstructured":"Zwilling, D. et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863\u2013874 (2011).","journal-title":"Cell"},{"key":"84858_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.expneurol.2016.05.005","volume":"282","author":"V Beaumont","year":"2016","unstructured":"Beaumont, V. et al. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington\u2019s disease. Exp. Neurol. 282, 99\u2013118 (2016).","journal-title":"Exp. Neurol."},{"key":"84858_CR13","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1073\/pnas.1604453113","volume":"113","author":"C Breda","year":"2016","unstructured":"Breda, C. et al. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proc. Natl. Acad. Sci. 113, 5435\u20135440 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"84858_CR14","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist, M. et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J. Exp. Med. 205, 1869\u20131877 (2008).","journal-title":"J. Exp. Med."},{"key":"84858_CR15","doi-asserted-by":"publisher","first-page":"RRN1231","DOI":"10.1371\/currents.RRN1231","volume":"3","author":"E Wild","year":"2011","unstructured":"Wild, E. et al. Abnormal peripheral chemokine profile in Huntington\u2019s disease. PLoS Curr. 3, RRN1231\u2013RRN1231 (2011).","journal-title":"PLoS Curr."},{"key":"84858_CR16","doi-asserted-by":"publisher","first-page":"11447","DOI":"10.1038\/s41598-018-29792-x","volume":"8","author":"J Pido-Lopez","year":"2018","unstructured":"Pido-Lopez, J. et al. In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington\u2019s disease. Sci. Rep. 8, 11447 (2018).","journal-title":"Sci. Rep."},{"key":"84858_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/jnc.13008","volume":"132","author":"DN Doll","year":"2015","unstructured":"Doll, D. N., Rellick, S. L., Barr, T. L., Ren, X. & Simpkins, J. W. Rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity. J. Neurochem. 132, 443\u2013451 (2015).","journal-title":"J. Neurochem."},{"key":"84858_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnins.2014.00012","volume":"8","author":"B Campbell","year":"2014","unstructured":"Campbell, B., Charych, E., Lee, A. & M\u00f6ller, T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front. Neurosci. 8, 12 (2014).","journal-title":"Front. Neurosci."},{"key":"84858_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neulet.2008.06.007","volume":"441","author":"TJ Connor","year":"2008","unstructured":"Connor, T. J., Starr, N., O\u2019Sullivan, J. B. & Harkin, A. Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-\u03b3?. Neurosci. Lett. 441, 29\u201334 (2008).","journal-title":"Neurosci. Lett."},{"key":"84858_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s42003-019-0520-5","volume":"2","author":"S Zhang","year":"2019","unstructured":"Zhang, S. et al. A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Commun. Biol. 2, 271 (2019).","journal-title":"Commun. Biol."},{"key":"84858_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","volume":"23","author":"P Guidetti","year":"2006","unstructured":"Guidetti, P. et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 23, 190\u2013197 (2006).","journal-title":"Neurobiol. Dis."},{"key":"84858_CR22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1471-4159.2010.06675.x","volume":"113","author":"KV Sathyasaikumar","year":"2010","unstructured":"Sathyasaikumar, K. V. et al. Dysfunctional kynurenine pathway metabolism in the R6\/2 mouse model of Huntington\u2019s disease. J. Neurochem. 113, 1416\u20131425 (2010).","journal-title":"J. Neurochem."},{"key":"84858_CR23","doi-asserted-by":"publisher","first-page":"36554","DOI":"10.1074\/jbc.M113.503813","volume":"288","author":"F Giorgini","year":"2013","unstructured":"Giorgini, F. et al. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J. Biol. Chem. 288, 36554\u201336566 (2013).","journal-title":"J. Biol. Chem."},{"key":"84858_CR24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.nbd.2014.10.012","volume":"73","author":"U Tr\u00e4ger","year":"2015","unstructured":"Tr\u00e4ger, U. et al. Characterisation of immune cell function in fragment and full-length Huntington\u2019s disease mouse models. Neurobiol. Dis. 73, 388\u2013398 (2015).","journal-title":"Neurobiol. Dis."},{"key":"84858_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/npp.2011.277","volume":"37","author":"PA Zunszain","year":"2012","unstructured":"Zunszain, P. A. et al. Interleukin-1\u03b2: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37, 939\u2013949 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"84858_CR26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/eji.1830111013","volume":"11","author":"JM Austyn","year":"1981","unstructured":"Austyn, J. M. & Gordon, S. F4\/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur. J. Immunol. 11, 805\u2013815 (1981).","journal-title":"Eur. J. Immunol."},{"key":"84858_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","volume":"130","author":"D Jauch","year":"1995","unstructured":"Jauch, D. et al. Dysfunction of brain kynurenic acid metabolism in Huntington\u2019s disease: focus on kynurenine aminotransferases. J. Neurol. Sci. 130, 39\u201347 (1995).","journal-title":"J. Neurol. Sci."},{"key":"84858_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","volume":"17","author":"P Guidetti","year":"2004","unstructured":"Guidetti, P., Luthi-Carter, R. E., Augood, S. J. & Schwarcz, R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington\u2019s disease. Neurobiol. Dis. 17, 455\u2013461 (2004).","journal-title":"Neurobiol. Dis."},{"key":"84858_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0021-9258(18)70659-5","volume":"228","author":"FT De Castro","year":"1957","unstructured":"De Castro, F. T., Brown, R. R. & Price, J. M. The intermediary metabolism of tryptophan by cat and rat tissue preparations. J. Biol. Chem. 228, 777\u2013784 (1957).","journal-title":"J. Biol. Chem."},{"key":"84858_CR30","doi-asserted-by":"publisher","first-page":"541259","DOI":"10.1155\/2013\/541259","volume":"2013","author":"G Ellrichmann","year":"2013","unstructured":"Ellrichmann, G., Reick, C., Saft, C. & Linker, R. A. The role of the immune system in Huntington\u2019s disease. Clin. Dev. Immunol. 2013, 541259 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"84858_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1046\/j.1471-4159.2002.00955.x","volume":"82","author":"T Kita","year":"2002","unstructured":"Kita, T., Morrison, P. F., Heyes, M. P. & Markey, S. P. Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the l-kynurenine and quinolinic acid pools in brain. J. Neurochem. 82, 258\u2013268 (2002).","journal-title":"J. Neurochem."},{"key":"84858_CR32","doi-asserted-by":"publisher","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","volume":"32","author":"J Bouchard","year":"2012","unstructured":"Bouchard, J. et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington\u2019s disease. J. Neurosci. 32, 18259\u201318268 (2012).","journal-title":"J. Neurosci."},{"key":"84858_CR33","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddu151","volume":"23","author":"H-Y Hsiao","year":"2014","unstructured":"Hsiao, H.-Y. et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington\u2019s disease. Hum. Mol. Genet. 23, 4328\u20134344 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"84858_CR34","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.3390\/ijms21072431","volume":"21","author":"M Tanaka","year":"2020","unstructured":"Tanaka, M., Toldi, J. & V\u00e9csei, L. Exploring the etiological links behind neurodegenerative diseases: inflammatory cytokines and bioactive kynurenines. Int. J. Mol. Sci. 21, 2431 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"84858_CR35","first-page":"63","volume":"11","author":"L Song","year":"2017","unstructured":"Song, L., Pei, L., Yao, S., Wu, Y. & Shang, Y. NLRP3 inflammasome in neurological diseases, from functions to therapies. Front. Cell. Neurosci. 11, 63 (2017).","journal-title":"Front. Cell. Neurosci."},{"key":"84858_CR36","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.3390\/ijms19123851","volume":"19","author":"DR Neavin","year":"2018","unstructured":"Neavin, D. R., Liu, D., Ray, B. & Weinshilboum, R. M. The role of the aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases. Int. J. Mol. Sci. 19, 3851 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"84858_CR37","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/ni.2705","volume":"14","author":"LC Davies","year":"2013","unstructured":"Davies, L. C., Jenkins, S. J., Allen, J. E. & Taylor, P. R. Tissue-resident macrophages. Nat. Immunol. 14, 986\u2013995 (2013).","journal-title":"Nat. Immunol."},{"key":"84858_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c120026","author":"LJ Dixon","year":"2013","unstructured":"Dixon, L. J., Barnes, M., Tang, H., Pritchard, M. T. & Nagy, L. E. Kupffer cells in the liver. Compr. Physiol. https:\/\/doi.org\/10.1002\/cphy.c120026 (2013).","journal-title":"Compr. Physiol."},{"key":"84858_CR39","first-page":"101","volume":"1","author":"AT Nguyen-Lefebvre","year":"2015","unstructured":"Nguyen-Lefebvre, A. T. & Horuzsko, A. Kupffer cell metabolism and function. J. Enzymol. Metab. 1, 101 (2015).","journal-title":"J. Enzymol. Metab."},{"key":"84858_CR40","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958\u2013969 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"84858_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","volume":"5","author":"G Arango Duque","year":"2014","unstructured":"Arango Duque, G. & Descoteaux, A. Macrophage cytokines: involvement in immunity and infectious diseases. Front. Immunol. 5, 491 (2014).","journal-title":"Front. Immunol."},{"key":"84858_CR42","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3389\/fimmu.2017.01957","volume":"8","author":"E Wirthgen","year":"2018","unstructured":"Wirthgen, E., Hoeflich, A., Rebl, A. & G\u00fcnther, J. Kynurenic acid: the Janus-faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions. Front. Immunol. 8, 1957 (2018).","journal-title":"Front. Immunol."},{"key":"84858_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11010-017-2975-3","volume":"431","author":"S Salimi Elizei","year":"2017","unstructured":"Salimi Elizei, S., Poormasjedi-Meibod, M.-S., Wang, X., Kheirandish, M. & Ghahary, A. Kynurenic acid downregulates IL-17\/1L-23 axis in vitro. Mol. Cell. Biochem. 431, 55\u201365 (2017).","journal-title":"Mol. Cell. Biochem."},{"key":"84858_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","volume":"48","author":"C Guti\u00e9rrez-V\u00e1zquez","year":"2018","unstructured":"Guti\u00e9rrez-V\u00e1zquez, C. & Quintana, F. J. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity 48, 19\u201333 (2018).","journal-title":"Immunity"},{"key":"84858_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493\u2013506 (1996).","journal-title":"Cell"},{"key":"84858_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ana.10094","volume":"51","author":"E Hockly","year":"2002","unstructured":"Hockly, E. et al. Environmental enrichment slows disease progression in R6\/2 Huntington\u2019s disease mice. Ann. Neurol. 51, 235\u2013242 (2002).","journal-title":"Ann. Neurol."},{"key":"84858_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/hmg\/ddp467","volume":"19","author":"K Sathasivam","year":"2010","unstructured":"Sathasivam, K. et al. Identical oligomeric and fibrillar structures captured from the brains of R6\/2 and knock-in mouse models of Huntington\u2019s disease. Hum. Mol. Genet. 19, 65\u201378 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"84858_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1750-1326-3-17","volume":"3","author":"CL Benn","year":"2008","unstructured":"Benn, C. L., Fox, H. & Bates, G. P. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington\u2019s disease. Mol. Neurodegener. 3, 17 (2008).","journal-title":"Mol. Neurodegener."},{"key":"84858_CR49","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"84858_CR50","doi-asserted-by":"crossref","unstructured":"Landles, C. et al. Subcellular localization and formation of huntingtin aggregates correlates with symptom onset and progression in a Huntington\u2019s disease model. Brain Commun. 2(2), (2020).","DOI":"10.1093\/braincomms\/fcaa066"},{"key":"84858_CR51","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ar.22641","volume":"296","author":"EC Jensen","year":"2013","unstructured":"Jensen, E. C. Quantitative analysis of histological staining and fluorescence using ImageJ. Anat. Rec. 296, 378\u2013381 (2013).","journal-title":"Anat. Rec."},{"key":"84858_CR52","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0361-9230(03)00185-0","volume":"61","author":"E Hockly","year":"2003","unstructured":"Hockly, E., Woodman, B., Mahal, A., Lewis, C. M. & Bates, G. Standardization and statistical approaches to therapeutic trials in the R6\/2 mouse. Brain Res. Bull. 61, 469\u2013479 (2003).","journal-title":"Brain Res. Bull."},{"key":"84858_CR53","doi-asserted-by":"crossref","unstructured":"Pido-Lopez, J. et al. Inhibition of tumour necrosis factor alpha in the R6\/2 mouse model of Huntington\u2019s disease by etanercept treatment. Sci. Rep. 9(1), (2019).","DOI":"10.1038\/s41598-019-43627-3"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84858-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T19:21:31Z","timestamp":1698002491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84858-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["84858"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-84858-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FG has a patent application\u2014KYNURENINE 3-MONOOXYGENASE (KMO) INHIBITORS, AND USES AND COMPOSITIONS THEREOF\u2014pending. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5484"}}